A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

Axel Bex, Laurence Albiges, Michael Staehler, Karim Bensalah, Rachel H. Giles, Saeed Dabestani, Fabian Hofmann, Milan Hora, Markus A. Kuczyk, Thomas B. Lam, Lorenzo Marconi, Axel S. Merseburger, Sergio Fernández-Pello, Rana Tahbaz, Yasmin Abu-Ghanem, Alessandro Volpe, Börje Ljungberg, Bernard Escudier, Thomas Powles

Research output: Contribution to journalLetterpeer-review

3 Citations (SciVal)
Original languageEnglish
Pages (from-to)849-851
Number of pages3
JournalEuropean Urology
Volume74
Issue number6
DOIs
Publication statusPublished - 2018

Subject classification (UKÄ)

  • Cancer and Oncology
  • Urology and Nephrology

Cite this